RNAC: Cartesian Therapeutics, Inc. Stock

by  •  • Comments Off on RNAC: Cartesian Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 434.76
Enterprise Value ($M) 658.40
Book Value ($M) -139.63
Book Value / Share -7.85
Price / Book -3.11
NCAV ($M) -353.95
NCAV / Share -19.89
Price / NCAV -1.23

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -15.04
Return on Equity (ROE) -18.17

Liquidity (mrq)
Quick Ratio 1.33
Current Ratio 1.33

Balance Sheet (mrq) ($M)
Current Assets 90.73
Assets 305.05
Liabilities 444.68
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 26.00
Operating Income -86.42
Net Income -219.71
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -51.16
Cash from Investing 34.61
Cash from Financing -13.14

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-12 13D/A Springer Timothy A 36.40 -96.67
04-10 13D/A Singer Michael 4.30 -97.05
04-10 13D/A Kalayoglu Murat 19.90 -91.01
03-11 13G/A Fmr Llc 10.42 27.25
02-14 13G/A Mangrove Partners 2.59 -56.04
02-09 13G/A Artal International S.C.A. 6.40 2.44

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-07 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 23,718 132,678 17.88
2024-05-02 25,885 37,560 68.92
2024-05-01 20,097 16,701 120.33
2024-04-30 10,859 12,354 87.90
2024-04-29 112,004 23,260 481.53

(click for more detail)

Similar Companies
RCKT – Rocket Pharmaceuticals, Inc. RLAY – Relay Therapeutics, Inc.
RNA – Avidity Biosciences, Inc. RPHM – Reneo Pharmaceuticals, Inc.
RVNC – Revance Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io